CLINICAL AND PARA-CLINICAL CHARACTERISTICS OF RECURRENT NASOPHARYNGEAL CARCINOMA: A STUDY AT K HOSPITAL

Văn Đăng Nguyễn, Anh Văn Nguyễn

Main Article Content

Abstract

Objective: To describe some clinical and para-clinical features of patients with recurrent nasopharyngeal carcinoma at National Cancer Hospital from June 2022 to September 2024. Patients and Methods: A retrospective study was conducted on 39 patients diagnosed with recurrent nasopharyngeal carcinoma at the Head and Neck Radiation Department of K Hospital from June 2022 to September 2024. Results: The average age was 53.9 ± 10 years [39–78], with a male-to-female ratio of 2:1. Headache was the most common reason for hospital admission, accounting for 33.3%. Patients in stages III and IVa before initial treatment had a high recurrence rate, comprising 76.9% of the cases. At recurrence, the predominant stage was IVa (25.6%). The average time to recurrence was 30.3 ± 16.6 months [8.53–71.63]. Conclusion: Recurrent nasopharyngeal carcinoma is more commonly observed in middle-aged male patients, predominantly at stage IVa, and frequently occurs within the first two years after treatment.

Article Details

References

Chen YH, Luo SD, Wu SC, et al. Clinical Characteristics and Predictive Outcomes of Recurrent Nasopharyngeal Carcinoma-A Lingering Pitfall of the Long Latency. Cancers. 2022; 14(15):3795. doi:10.3390/cancers14153795
2. Tuấn NA, Chinh HĐ, Biểu BQ, và cộng sự. Kết quả hóa xạ trị điều biến liều ung thư vòm mũi họng giai đoạn II-III. Tạp Chí Học Việt Nam. 2023;530(1B). doi:10.51298/vmj.v530i1B.6752
3. Argirion I, Zarins KR, Suwanrungruang K, et al. Subtype Specific Nasopharyngeal Carcinoma Incidence and Survival Trends: Differences between Endemic and Non-Endemic Populations. Asian Pac J Cancer Prev APJCP. 2020;21(11): 3291. doi:10.31557/APJCP.2020.21.11.3291
4. Peng Z, Wang Y, Fan R, et al. Treatment of Recurrent Nasopharyngeal Carcinoma: A Sequential Challenge. Cancers. 2022;14(17):4111. doi:10.3390/cancers14174111
5. Hiếu TĐ. Đánh giá kết quả điều trị ung thư vòm mũi họng giai đoạn tái phát hoặc di căn bằng phác đồ Gemcitabin - Cisplatin tại Bệnh viện Ung bướu Nghệ An. Tạp Chí Dược Thái Bình. Published online November 6, 2023:99-107.
6. Treatment by Cancer Type. NCCN. Accessed October 24, 2024. https://www.nccn.org/ guidelines/category_1
7. Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019; 381(12): 1124-1135. doi:10.1056/ NEJMoa1905287
8. Hwang JM, Fu KK, Phillips TL. Results and prognostic factors in the retreatment of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1998;41(5):1099-1111. doi:10. 1016/s0360-3016(98)00164-3
9. Teo PM, Kwan WH, Chan AT, et al. How successful is high-dose (>or = 60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma? Int J Radiat Oncol Biol Phys. 1998; 40(4): 897-913. doi:10.1016/s0360-3016 (97)00854-7
10. Ng WT, Soong YL, Ahn YC, et al. International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2021;110(3):682-695. doi:10.1016/j.ijrobp.2021.01.041